Supriya Lifesci.

how big is Supriya Lifesci.?

As of Jun 06, Supriya Lifescience Ltd has a market capitalization of 5,593.00 Cr, with recent net sales of 696.49 Cr and a net profit of 187.95 Cr. The standalone balance sheet shows shareholder's funds of 815.37 Cr and total assets of 921.24 Cr.

Market Cap: As of Jun 06, Supriya Lifescience Ltd has a market capitalization of 5,593.00 Cr, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: For the latest 4 quarters, Supriya Lifescience Ltd reported Net Sales of 696.49 Cr and a Net Profit of 187.95 Cr. This data is based on Standalone financials.<BR><BR>Balance Sheet Snapshot: The Standalone balance sheet for the latest annual period ending in Mar'24 shows Shareholder's Funds of 815.37 Cr and Total Assets of 921.24 Cr.

What does Supriya Lifesci. do?

Supriya Lifescience Ltd is a mid-cap company in the Pharmaceuticals & Biotechnology industry, incorporated in 2008, with net sales of 184 Cr and a net profit of 50 Cr as of March 2025. Key metrics include a P/E ratio of 30, a market cap of Rs 5,581 Cr, and a return on equity of 20.75%.

Overview:<BR>Supriya Lifescience Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Mid Cap company.<BR><BR>History:<BR>Supriya Lifescience Limited was incorporated as a Public Limited Company on March 26, 2008, following its conversion from a partnership firm originally established as M/s Supriya Chemicals on October 29, 1985. The latest quarterly results report net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 184 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 50 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 5,581 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>- P/E: 30.00<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.11%<BR>- Debt Equity: -0.09<BR>- Return on Equity: 20.75%<BR>- Price to Book: 6.19<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Who are in the management team of Supriya Lifesci.?

As of March 2022, the management team of Supriya Lifesci includes Satish Waman Wagh (Chairman & Managing Director), Smita Satish Wagh, Soloni Satish Wagh, Shivani Satish Wagh, Balasahab Gulabrao Sawant (Whole-time Directors), and several Independent Directors, along with Shweta Shivdhari Singh as Company Secretary.

As of March 2022, the management team of Supriya Lifesci includes the following individuals:<BR><BR>1. Satish Waman Wagh - Chairman & Managing Director<BR>2. Smita Satish Wagh - Whole-time Director<BR>3. Soloni Satish Wagh - Whole-time Director<BR>4. Shivani Satish Wagh - Whole-time Director<BR>5. Balasahab Gulabrao Sawant - Whole-time Director<BR>6. Kedar Shankar Karmarkar - Independent Director<BR>7. Bhairav Manojbhai Chokshi - Independent Director<BR>8. Dileep Kumar Jain - Independent Director<BR>9. Dinesh N Modi - Independent Director<BR>10. Neelam Yashpal Arora - Independent Director<BR>11. Shweta Shivdhari Singh - Company Secretary & Compliance Officer<BR>12. Manoj Deo Dorlikar - Whole-time Director & Additional Director<BR><BR>This team comprises a mix of executive and independent directors, along with key compliance personnel.

Has Supriya Lifesci. declared dividend?

Yes, Supriya Lifescience Ltd has declared a 40% dividend, amounting to ₹0.80 per share, with an ex-date of September 20, 2024. While the recent total returns have been negative over the last 6 months, the company has shown significant growth in longer periods.

Supriya Lifescience Ltd has declared a 40% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 40%<BR>- Amount per share: ₹0.80<BR>- Ex-date: 20 Sep 2024<BR><BR>Dividend Yield: 0.11%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -10.25%, with a dividend return of 0%, resulting in a total return of -10.25%.<BR><BR>Over the past year, the price return was 95.83%, the dividend return was 0.21%, leading to a total return of 96.04%.<BR><BR>In the 2-year period, the price return was 169.88%, the dividend return was 0.56%, culminating in a total return of 170.44%.<BR><BR>For the 3-year period, the price return was 92.15%, with a dividend return of 0.62%, resulting in a total return of 92.77%.<BR><BR>In the 4-year period, both the price and dividend returns were 0%, leading to a total return of 0.0%.<BR><BR>Over the last 5 years, there were no price or dividend returns, resulting in a total return of 0.0%.<BR><BR>Overall, Supriya Lifescience Ltd has declared a dividend, and while the recent total returns show significant growth over longer periods, the short-term performance has been negative. The dividend yield indicates a modest return from dividends relative to the share price.

Who are the peers of the Supriya Lifesci.?

Supriya Lifesci.'s peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Innova Captab, Sequent Sciences, Hikal, Dishman Carbogen, and Unichem Labs. Supriya Lifesci. has a 1-year return of 101.13%, significantly higher than its peers, with varying management risks and capital structures among them.

Peers: The peers of Supriya Lifesci. are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Innova Captab, Sequent Scien., Hikal, Dishman Carbogen, and Unichem Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Hikal, and Supriya Lifesci., while Average management risk is found at Innova Captab, Sequent Scien., Dishman Carbogen, and Unichem Labs. Growth is excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is noted for Divi's Lab., Torrent Pharma, Supriya Lifesci., Hikal, Sequent Scien., and Dishman Carbogen, and the rest. Excellent capital structure is seen in Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs., Supriya Lifesci., and Innova Captab, while Average capital structure is found at Hikal and Good capital structure at Torrent Pharma and Unichem Labs, with the rest having Below Average.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.96%, while the lowest is Cipla at 0.86%. Supriya Lifesci.'s 1-year return is significantly higher at 101.13%. Additionally, the peers with negative six-month returns include Innova Captab, Sequent Scien., Hikal, and Unichem Labs.

Who are the top shareholders of the Supriya Lifesci.?

The top shareholders of Supriya Lifesci include promoter Satish Waman Wagh with 67.64%, 78 Foreign Institutional Investors holding 7.19%, and individual investors at 16.4%. The highest public shareholder is the Cohesion Mk Best Ideas Sub-trust with 2.06%.

The top shareholders of Supriya Lifesci include the promoters, with Satish Waman Wagh holding the highest stake at 67.64%. There are also 78 Foreign Institutional Investors (FIIs) who collectively hold 7.19% of the company. Additionally, mutual funds are represented by 8 schemes, holding 0.66%. The highest public shareholder is the Cohesion Mk Best Ideas Sub-trust, which holds 2.06%. Individual investors account for 16.4% of the total holdings.

Is Supriya Lifesci. overvalued or undervalued?

As of September 18, 2025, Supriya Lifesci. is considered very expensive and overvalued with a PE ratio of 31.26, an EV to EBITDA of 21.96, and a Price to Book Value of 5.59, despite a 10.11% return over the past year, which outperformed the Sensex's 0.08% return.

As of 18 September 2025, the valuation grade for Supriya Lifesci. has moved from expensive to very expensive, indicating a significant shift in its perceived market value. The company is currently considered overvalued. Key ratios include a PE ratio of 31.26, an EV to EBITDA of 21.96, and a Price to Book Value of 5.59, all of which suggest that the stock is trading at a premium compared to its earnings and asset values.<BR><BR>In comparison to its peers, Supriya Lifesci. has a higher PE ratio than Sun Pharma (34.46) and a significantly lower PEG ratio of 0.99 compared to Divi's Lab (1.87), which indicates that while growth expectations are considered, the current valuation may not be justified. Additionally, the company's recent stock performance shows a 10.11% return over the past year, outperforming the Sensex's 0.08% return, which may reflect investor optimism despite the overvaluation concerns.

How has been the historical performance of Supriya Lifesci.?

Supriya Lifesci has shown significant growth from March 2020 to March 2025, with net sales increasing from 311.64 Cr to 696.49 Cr, and profit after tax rising from 73.37 Cr to 187.96 Cr. The company's total assets also grew from 336.15 Cr to 1,112.31 Cr, indicating strong overall financial performance.

Answer:<BR>The historical performance of Supriya Lifesci shows significant growth in net sales and profitability over the years, culminating in the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Supriya Lifesci's net sales have increased from 311.64 Cr in March 2020 to 696.49 Cr in March 2025, reflecting a strong upward trend. Total operating income followed a similar trajectory, rising from 311.64 Cr in March 2020 to 696.49 Cr in March 2025. The company's operating profit (PBDIT) has also shown substantial growth, reaching 270.62 Cr in March 2025, up from 109.45 Cr in March 2020. Profit before tax increased from 96.20 Cr in March 2020 to 248.48 Cr in March 2025, while profit after tax rose from 73.37 Cr to 187.96 Cr in the same period. The earnings per share (EPS) improved significantly, from 10.02 in March 2020 to 23.35 in March 2025. On the balance sheet, total assets grew from 336.15 Cr in March 2020 to 1,112.31 Cr in March 2025, with total liabilities increasing from 336.15 Cr to 1,112.31 Cr as well. Cash flow from operating activities improved from 116.00 Cr in March 2020 to 164.00 Cr in March 2025, indicating a positive cash generation trend. Overall, Supriya Lifesci has demonstrated robust growth in sales, profitability, and asset base over the past five years.

Is Supriya Lifesci. technically bullish or bearish?

As of December 4, 2025, Supriya Lifesci's trend is mildly bullish, supported by mixed indicators such as a bullish weekly MACD and KST, while facing bearish signals on the monthly RSI and Dow Theory showing no clear trend.

As of 4 December 2025, the technical trend for Supriya Lifesci has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is mildly bearish, indicating mixed signals across time frames. The RSI shows no signal on the weekly chart but is bearish on the monthly, suggesting weakening momentum. Bollinger Bands are mildly bullish on both weekly and monthly charts, supporting a positive outlook. Daily moving averages are mildly bullish, reinforcing the short-term positive sentiment. KST is bullish on both weekly and monthly time frames, and OBV is bullish weekly, indicating accumulation. However, Dow Theory shows no trend in both weekly and monthly perspectives. Overall, the current stance is mildly bullish, driven by the mixed indicators, particularly the weekly MACD and KST.

When is the next results date for Supriya Lifescience Ltd?

The next results date for Supriya Lifescience Ltd is February 9, 2026.

The next results date for Supriya Lifescience Ltd is scheduled for February 9, 2026.

Are Supriya Lifescience Ltd latest results good or bad?

Supriya Lifescience Ltd's latest Q2 FY26 results show a strong recovery with a 44.97% increase in net profit and a 37.75% rise in revenue. However, a decline in operating margin raises concerns about ongoing profitability pressures, leading to a mixed overall assessment of the results.

Supriya Lifescience Ltd's latest results for Q2 FY26 show a mixed performance. On the positive side, the company reported a net profit of ₹50.43 crore, which is a significant increase of 44.97% quarter-on-quarter (QoQ). Additionally, revenue grew to ₹199.83 crore, reflecting a 37.75% QoQ increase. This indicates a strong recovery from the previous quarter's disappointing results.<BR><BR>However, there are concerns regarding the operating margin, which decreased to 36.35% from 38.96% in the same quarter last year, marking a contraction of 261 basis points. This decline suggests that the company is facing persistent pressures on profitability, likely due to rising input costs and competitive dynamics in the pharmaceutical sector.<BR><BR>Overall, while the recovery in net profit and revenue growth is encouraging, the margin compression raises questions about the sustainability of profitability moving forward. The stock has also underperformed the broader market over the past year, which adds to the cautious outlook. Therefore, the results can be seen as good in terms of growth recovery but bad concerning profitability pressures.

Should I buy, sell or hold Supriya Lifescience Ltd?

Which are the latest news on Supriya Lifesci.?

Why is Supriya Lifescience Ltd falling/rising?

As of 06-May, Supriya Lifescience Ltd's stock price is at 703.45, reflecting a 1.46% increase. Despite underperforming its sector today, the stock shows a positive trend with institutional investor confidence and strong financial health.

As of 06-May, Supriya Lifescience Ltd's stock price is rising, currently at 703.45, reflecting a change of 10.15 (1.46%) upward. The stock has been gaining for the last two days, with a total increase of 1.55% during this period. Additionally, the stock touched an intraday high of Rs 710.4, which represents a 2.47% increase. <BR><BR>Despite today's performance showing that the stock underperformed its sector by 1.02%, it is important to note that the Pharmaceuticals & Drugs sector has gained by 2.41%. The stock is also trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a positive trend in its price movement.<BR><BR>Moreover, there has been increasing participation by institutional investors, who have raised their stake by 0.65% over the previous quarter, now holding 10.86% of the company. This suggests a growing confidence among more sophisticated investors regarding the company's fundamentals. The company is also net-debt free and has demonstrated high management efficiency with a return on equity (ROE) of 17.74%.<BR><BR>However, it is worth mentioning that the stock has experienced a decline in investor participation, with delivery volume dropping by 73.32% compared to the 5-day average. Despite this, the overall positive factors, such as consistent returns over the last three years and the company's financial health, contribute to the current rise in the stock price.